Product Usage
This product is intended for research purposes only. All product information available on this website is for educational purposes only. This product is not intended for consumption or bodily introduction of any kind. It should only be handled by licensed and qualified professionals. It is not a drug, food, or cosmetic, and must not be misbranded, misused, or mislabeled as such.
Tesamorelin
PURITY ≥99%/THIRD-PARTY TESTED/HPLC VERIFIED
Tesamorelin — Enhanced GHRH Receptor Agonist. 2 mg / 10 mg.
FDA Disclaimer: The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. All products are for laboratory developmental research USE ONLY. Not intended for consumption of any kind.
03 / Research Context
Research context
Tesamorelin is a GHRH analog with an N-terminal trans-3-hexenoic acid modification. It exhibits enhanced receptor binding affinity and metabolic stability, significantly modulating lipid metabolism and IGF-1 transcription.
Key research areas
- FDA-approved for visceral fat reduction (Egrifta)
- Up to 18% visceral adipose tissue reduction
- Up to 37% hepatic (liver) fat reduction
- Improved lipid profiles and cardiovascular markers
- Most potent GHRH analog available
- IGF-1 normalization in clinical studies
Handling & reconstitution
Supplied as a lyophilized powder. Bacteriostatic water is the recommended solvent for reconstitution in research applications. Store unreconstituted product at -20°C; reconstituted solutions should be stored at 2-8°C and used within 14–30 days.
Research use only. Not for human consumption.
Product specifications
| Type | Enhanced GHRH Receptor Agonist |
| Composition | 2 mg / 10 mg |
| Purity | 99%+ |
| Appearance | Lyophilized Powder |
| Storage | 2-8°C |
